The First 100 Believed Before It Was Obvious

PleoPharma

PleoPharma just added $6.5M in federal support to one of biotech’s more ignored fights: helping people get through cannabis withdrawal without pretending the condition disappears as cannabis becomes normalized.

The three-year NIDA grant will support CAN-004, its pivotal Phase 3 study of PP-01. The investigational oral therapy is being evaluated for withdrawal symptoms in adults with moderate to severe cannabis use disorder.

That distinction matters. This is not an equity round with a valuation headline and a founder photo next to a term sheet. It is public research funding tied to evidence generation, trial execution, and a clinical problem living in the gap between cultural normalization and medical reality.

The gap is not small. SAMHSA’s 2024 national survey estimated that 20.6M people in the U.S. had cannabis use disorder. Yet there is still no FDA-approved medication for cannabis withdrawal syndrome or cannabis use disorder. This is a large market still underserved by medicine. That is the gap this program is trying to close with clinical evidence.

CAN-004 is recruiting. ClinicalTrials.gov lists the PleoPharma-sponsored Phase 3 study at an estimated 420 participants, with placebo and active controls. PP-01 remains investigational, and Fast Track designation is not approval, but the program has reached the part of biotech where claims have to survive a protocol, not a pitch deck.

PleoPharma says its Phase 2b CAN-002 study met the primary endpoint, showed a dose response, and reported no serious adverse events. Phase 3 now has to test safety and efficacy at pivotal scale, with primary completion estimated for July 2027.

The company did not arrive here on grant money alone. PleoPharma announced a $17.5M Series A in 2023 and a $36M Series B in 2025, both aimed at advancing PP-01. The NIDA award adds capital while placing a federal research institution behind the seriousness of the unmet need.

PleoPharma was founded in 2019 by Ginger Constantine, M.D., CEO, co-founder, and chairperson, and Jay Constantine, M.D., CMO, co-founder, and director. Shelli Graham, Ph.D., SVP of Medical/Clinical Research, is helping carry the program through late-stage clinical development.

Grants are not easy money. They are evidence money. They buy another chance to answer the only question that matters in drug development: does the treatment work well enough, safely enough, for patients who need an option that does not yet exist? That answer still has to be earned. But $6.5M says the question is finally getting the institutional weight it deserves.

Quantizr

Quantizr just raised a $5M Seed round to bring modern financial operations to an industry that still asks spreadsheets, PDFs, inboxes, and exhausted humans to keep a tour economically honest.

TTV Capital led the round, with Jonathan Azu, Chris Kappy, and Andy Levine participating. TTV knows fintech infrastructure. Azu, Kappy, and Levine know what happens when financial decisions meet artists, managers, venues, promoters, and a calendar that does not care whether the settlement file is clean.

Quantizr sits in the middle of that mess. The company turns offers, deal memos, contracts, budgets, expenses, and settlements into structured operating data for artist managers, business managers, agents, and artist teams. Its recently expanded Quantizr Tour Financials product puts budgets, tour performance, settlements, and artist take-home into one shared view while there is still time to act.

That distinction matters. Most public debate about AI in music starts with creation, rights, and replacement. Quantizr is working a less glamorous but brutally practical lane: operational AI. It is not trying to write the song. It is trying to make sure the people building the tour can see what the tour is actually earning.

Joshua Litwack, Tim Nielsen, and Jeremy Salken built the company from finance, technology, law, and lived music-business experience. Quantizr publicly launched in November 2025 after more than a year of beta work with industry operators. That is not a product looking for a market. It is a response to work the market has already been doing badly, slowly, and expensively.

The business lesson is straightforward. Vertical software wins when it understands the ugly details general-purpose tools politely ignore. Live entertainment has different deal structures, document formats, participants, incentives, and timing pressures. The closer Quantizr gets to the actual financial workflow, the harder it becomes to replace with another spreadsheet wearing an AI sticker. That is leverage.

The $5M does not prove the category is won. Seed rounds never do. It does give Quantizr more room to turn early product credibility into repeatable adoption, deeper workflow ownership, and a financial system that artist teams may trust before the van leaves the lot. The live business has spent decades counting every ticket. Quantizr is making the case that it should understand every dollar too.

XBE

XBE added PSG to the ownership table, but the interesting part is what stayed put. Founder and CEO Sean Devine will keep leading the company and retain a significant ownership position. Banneker Partners, which invested in 2024, will also remain a significant owner. PSG is joining the build, not replacing the people who got XBE here. The amount and terms were not disclosed, keeping the real story in view.

XBE is building business-operations software for heavy materials, logistics, and construction, industries where a delayed truck, a disconnected dispatch system, or a late financial signal can turn a good day into an expensive archaeology project.

The platform connects scheduling, dispatch, pricing, finance, telematics, analytics, and bid forecasting. XBE reports 475M+ tons tracked, $3B+ in trucking costs managed, 19M+ material transactions, 3.4M+ driver shifts, and 50+ integrations. Those company-reported numbers make one point clearly: this software lives inside physical operations.

That footprint widened after Banneker's investment. XBE acquired PriceBee and Gauge, combined with BCMI, and pushed deeper into ready-mix, equipment intelligence, pricing, production, and delivery. In Q1 2026, it launched Agent XBE, its agentic superworkforce. In Q2, it introduced All-22, a simulation, optimization, and autonomy system built into BCMI Dispatch.

PSG Managing Director Bill Skarinka said XBE's founder-led, customer-driven approach was a major reason for the investment. PSG Principal Evan Ocko framed the job as giving Sean Devine and the team more capacity to accelerate innovation and expand the customer community over the long term.

That distinction matters. Capital can buy capacity. It cannot manufacture domain judgment on command. XBE spent a decade learning how asphalt, ready-mix, aggregates, trucking, sales, finance, and field execution collide. The value is making those workflows tell the same truth soon enough for an operator to act.

CTO Nick Campion leads an R&D organization tasked with turning that domain depth into a faster product engine. PSG's capital and software-growth experience should increase the pace, while Banneker's ownership and Sean Devine's leadership preserve continuity.

The next test is execution. Can XBE convert a broader platform, more talent, and a larger customer community into measurable margin, faster decisions, and autonomous work across industries that do not tolerate theory for long? That answer will be worth tracking.

RockRose Risk

RockRose Risk just raised a $12.5M Series A to attack a problem insurers have spent years pricing around instead of solving: wildfire risk does not shrink because a spreadsheet found a higher premium.

Crosslink Capital and Congruent Ventures co-led the round, with Nuveen participating. It follows a separate $9M Seed announced in March, putting RockRose Risk’s two disclosed 2026 rounds at $21.5M. The valuation and deal terms were not disclosed, which is fine. The business model is the more interesting number here.

RockRose Risk is building a technology-enabled brokerage for commercial and residential properties in wildfire-exposed markets across California, Colorado, and Nevada. It physically assesses properties, converts mitigation into evidence, and brings that risk story to carriers that might otherwise rely on a blunt ZIP-code model.

That distinction matters. A homeowner can clear defensible space, harden a roof, and reduce nearby fuel, only to discover the insurance model still sees the same neighborhood-level risk. Preparation becomes an expense with no visible reward. RockRose Risk is trying to make it an input to coverage and price.

Co-founder and CEO Andrew Engler says the company now works with about $7B of property, has secured average insurance discounts of 35%, and works with 27 carriers. Those are company-reported figures, but they show the scale of the thesis: better ground truth can change how risk gets placed.

The next move goes beyond brokerage. RockRose Risk plans to take on mitigation work such as tree trimming and roof upgrades, then use the improvements to negotiate with insurers. Andrew Engler said the company is considering a $30M to $40M credit facility for acquisitions. That facility is not closed, but the direction is clear.

This is where the Series A gets useful. Insurance commissions reward the placement of risk. RockRose Risk wants more of the model focused on reducing risk before placement. Connect assessment, mitigation, and insurance economics, and owners get a reason to invest before the fire while carriers get better evidence than another colored shape on a catastrophe map.

Swiss Re Institute says North American wildfire insured losses are growing faster than exposure alone can explain. The market does not need another description after the damage. It needs businesses that can reduce risk property by property, then prove the work to the people carrying it. Insurance becomes more durable when mitigation is part of the product.

Capitan Orthopedics

Capitan Orthopedics has closed an oversubscribed Seed round, bringing total capital raised to date to $4.1M. Precision matters: the company did not say the Seed round alone was $4.1M.

The round exceeded its intended amount by more than $1.1M, according to CEO Chance W. Leonard. Investors were not named, and neither valuation nor deal terms were disclosed. The clean read is that Capitan found more appetite than expected for a very specific shoulder problem.

Capitan is developing SupraSpacer, a metallic implant and seven-step procedure designed for patients with irreparable rotator cuff tears. When the tendon can no longer stabilize the joint, the humeral head can migrate upward, leaving pain, limited function, and a treatment decision that gets complicated fast.

The company says SupraSpacer is designed to restore spacing and alignment while preserving future surgical options. It is also built around a minimally invasive, bone-sparing workflow with sterile-packaged instruments for ambulatory surgery centers. In medtech, the operating-room choreography can matter almost as much as the hardware.

There is an important regulatory line here. Capitan announced FDA Breakthrough Device Designation in April, which can provide more intensive agency interaction and prioritized review. It is not FDA clearance, and Capitan's own site says SupraSpacer is not yet cleared.

That makes the use of proceeds more revealing than the round number. Capitan plans to continue project development and validation, then begin its first-in-human clinical trial in Q1 2027. This capital is being asked to turn a plausible mechanism into clinical evidence.

Chance W. Leonard leads Capitan and parent Genesis Innovation Group. R. Sean Churchill, MD, MBA, is on the surgeon design team and Capitan board while leading cultivate(MD). The company does not list a CTO.

What is still missing matters just as much. Capitan has not disclosed Seed investors, prior-round amounts, trial design, patient enrollment, pricing, reimbursement, or commercial timing. No human outcomes are available because the planned trial has not begun.

For Capitan, the next milestone will not be another adjective in a press release. It will be whether development discipline, clinical design, and regulatory execution can carry SupraSpacer from a compelling shoulder concept into credible patient data. Now comes the part where capital has to earn its place in the operating room.

Rundoo

Rundoo just raised a $30M Series B to give independent supply stores something the big boxes have treated like private property for years: software built around how the business actually runs. Battery Ventures led the round, with Bessemer Venture Partners and CRV returning, bringing Rundoo's total financing to $48M.

That is a serious check for a category most software companies barely notice. Hardware stores, paint dealers, lumber yards, garden centers, and farm and feed shops move the materials that keep communities working, yet many still manage inventory, contractor accounts, pricing, purchasing, and the front counter through systems old enough to remember dial-up.

Nick Hershey and Andrew Beckman started Rundoo to close that gap. Rundoo now says more than 500 independent stores across the U.S., Canada, and the Caribbean use its platform, which combines point of sale, inventory, purchasing, customer management, e-commerce, payments, and general-ledger functions in one operating layer.

Then comes Dooey, Rundoo's AI agent. It works across store data to answer questions, take actions, and automate repeatable jobs, so an owner can inspect margin, generate an order, follow up with a customer, or find an account that needs attention without translating the business into five disconnected tools first.

That distinction matters because AI for retail can become a costume department fast. Rundoo is building inside the system of record, where the model can see the transaction, inventory position, customer history, and purchasing workflow, then help the operator do something useful with it.

The company also has a distribution advantage hiding in plain sight. Rundoo connects with the manufacturers, distributors, and buying groups these stores already depend on, pulling catalogs, cost files, promotions, and ordering workflows closer to the counter instead of asking owners to rebuild their world around another generic app.

The new capital is earmarked for more engineering hiring in Redwood City, go-to-market growth in Chicago, and continued product development. The larger test is whether Rundoo can expand across several supply-store categories while protecting the service and workflow depth that got more than 500 shops to trust it with the daily machinery of the business. The operator lesson is clean: vertical AI gets interesting when it stops performing intelligence and starts carrying operational weight.

Grounded

Grounded just closed a $5M Seed and paired it with a 50,000-square-foot Detroit manufacturing expansion. The company says the move will increase capacity by 1,900% and support a new vehicle-agnostic box platform for commercial and municipal fleets.

Capital without a production system is expensive optimism, and a factory without demand is a large room full of confidence. Grounded is tying the round to tooling, equipment, R&D, facility buildout, and the talent needed to turn custom mobility into repeatable output.

Founder and CEO Sam Shapiro started Grounded in 2022, later joined by co-founder and Head of Design Nick Fitzpatrick. The original electric-camper beachhead now spans modular clinics, dental units, command centers, food-service vehicles, field-service platforms, and specialty fleets.

Grounded does not pretend one chassis can survive every policy cycle or procurement reality. The company builds the modular interior, power system, connected software, and fleet-control layer above platforms from Ford, Harbinger, GM, and Rivian, giving operators flexibility across electric, hybrid, and conventional options.

Chief Product Officer Nadia Meyer describes demand from an economy increasingly moving onto wheels. Grounded names Colgate, Nokia, and Wayne State University Medical among customers across mobile health, dental care, food service, and field operations.

Production at the new Detroit facility is scheduled to begin in August 2026 and ramp through 2027. Grounded also hired Drew Snow, formerly of Adrian Steel, as Director of International Sales, while the Detroit Economic Growth Corporation says the expansion supports 15 new jobs.

The investor list for this Seed was not disclosed, so there is no reason to decorate the cap table with guesses. Grounded’s prior $3.5M Pre-Seed was announced in October 2024 and co-led by The 81 Collection and Also Capital, with Side Door Ventures and named individuals participating.

The real signal is operational: Grounded is moving from proving modular, software-defined vehicles can work to proving they can be manufactured at fleet scale. Enterprise and municipal buyers do not purchase a vision. They purchase uptime, repeatability, serviceability, and delivery confidence.

The round puts weight behind a practical thesis: specialty mobility may be less about inventing another vehicle and more about building a configurable operating layer on top of the vehicles already carrying the work.

Renata Medical

Renata Medical closed a $25M Series D led by ARCHIMED, and the money is going toward a wider U.S. rollout of the Minima Stent System. That is the headline. The better story is what had to happen before a pediatric medical device company could earn a commercialization round at this stage.

Minima was built for neonates, infants, and young children with pulmonary artery stenoses or coarctation of the aorta. Those patients can weigh as little as 1.5 kg, and the vessels physicians need to reach may be smaller than a drinking straw. Adult-device logic does not shrink neatly into that anatomy.

So Renata Medical designed a stent system for small vessels and long timelines. Minima uses a low-profile delivery system and can be re-expanded as a child grows. The point is practical: give physicians a tool created for the patient in front of them and reduce the chance that growth turns one intervention into recurring surgery.

The company crossed the FDA line in August 2024, launched commercially in the U.S., and secured a CMS New Technology Add-on Payment of up to $22,685 per eligible case. In July 2026, FDA approved the Minima Pro line extension with a hybrid open-cell design and a new 10 mm balloon option. Regulation, reimbursement, product iteration, then scale.

That sequence changes how the $25M should be read. This is not capital chasing a promising prototype. It is specialist healthcare money backing the operational grind after approval and proving that a purpose-built pediatric device can become durable commercial infrastructure. Only expanded U.S. commercialization was formally disclosed, but the stage of the company makes the assignment clear.

ARCHIMED brings a healthcare-only investment model and a global operating network to the table. Renata Medical brings a product that sits at the intersection of congenital heart care, medical-device engineering, reimbursement, and hospital adoption. The fit is less about financial theater and more about translating a hard-won approval into reach.

Co-founders Dustin Armer, CEO, and Eason Abbott, COO, started Renata Medical in 2019 after careers in cardiovascular device development. Chief Medical Officer Evan Zahn, MD, adds decades of pediatric interventional cardiology experience. The company built around a simple idea: the device should adapt to the child, not force the child into the limitations of the device.

TopHat Security

TopHat Security closed a Series A led by Landolt Securities, and the amount is not the most interesting part. It was not disclosed. The sharper signal is where the money is going: operational technology, critical infrastructure, government systems, and the AI infrastructure being wired into all three.

That territory does not tolerate testing in production and calling the smoke customer discovery. A bad software change can ruin a dashboard. A bad change inside a plant, utility, transportation system, or military environment can reach the physical world before the incident report finds a printer.

Founder and CEO Matt Caldwell built TopHat Security around that distinction. O-RANGE creates high-fidelity digital twins of industrial environments, including assets, network relationships, firmware, software, controls, and physical processes. Teams can model attack paths, investigate vulnerabilities, rehearse scenarios, and test remediation without treating live operations like a lab bench.

OT teams are buried in vulnerability information but still have to answer the expensive question: What happens if we touch this system? NIST's guidance is clear. OT security has to coexist with performance, reliability, and safety. A perfect control that interrupts production is not perfect. It is a new incident wearing a compliance badge.

Landolt Securities served as lead investor and placement agent. Don McKiernan, identified as a Landolt principal, framed the investment around national security and protecting government, critical infrastructure, and the AI systems attached to both. The thesis: digital and physical infrastructure are becoming one risk surface.

TopHat Security is not arriving with one shiny demo. Its portfolio spans OT discovery and scanning, industrial network visibility, cyber-supply-chain inspection, and AI-infrastructure defense through LIGHTFOOT, SEEKCAP, DDX, PARAGUARD, and SECONDLOOK XBOM.

The Series A will support O-RANGE, product development, customer delivery, and growth milestones. TopHat Security did not disclose the round size, valuation, other investors, or allocation. That is where disciplined coverage should leave the facts instead of filling the blanks with startup fan fiction.

Industrial operators need better cyber resilience. The next test is whether TopHat Security can turn safe simulation, operational context, and a broad product bench into repeatable delivery where downtime is measured in more than lost clicks.

Molt AI

Molt AI Corp. closed a $1M Pre-Seed round while launching Fisher, its assurance platform for tool-using AI agents. The check is $1M. The problem sitting behind it is considerably larger: an agent can say the right thing after it has already done the wrong thing.

That distinction matters because enterprise AI has acquired hands. Agents can query databases, read files, call APIs, send messages, and change system state. Security teams cannot govern those actions by grading only the last sentence.

Fisher is built around that gap. It runs adaptive, multi-turn adversarial campaigns, follows tool calls and state changes, records what the evidence supports, replays candidate failures, and attacks the remediation again. The point is not to produce a dramatic pile of alerts. It is to separate a one-off scare from a weakness an engineering team can reproduce and fix.

Molt reports more than 50,000 adversarial episodes, 500,000 conversation turns, and 20 model architectures as of July 2026. In matched tests, adaptive tactics raised verified attack success by 6.6 to 14.6 percentage points over static replays. Those are company-reported results, not a universal victory lap.

The company is led by co-founders Walton Comer, Chairman and CEO; Thomson Comer, CTO; and Greg Frank, Chief Scientist. Patrick Comer is the only publicly named participant in the financing. No lead investor, valuation, security, or full syndicate was disclosed, which means the intelligent read is about the operating thesis, not imaginary cap-table theater.

Proceeds are going toward Fisher, enterprise assessment and integration capacity, and further research into agent behavior, action-level evaluation, and verified remediation. That is a focused mandate for a young company entering a market where standards bodies are already moving. NIST has identified agent security as an adoption barrier, and OWASP now has a dedicated Top 10 for agentic applications.

The bigger signal is that AI assurance is moving beyond model evaluation. Once software can act across real systems, testing has to follow the action, preserve the evidence, and prove whether the fix holds. Otherwise, the dashboard can stay green while the agent quietly walks out carrying the keys.

The $1M funds the next stretch. The real wager is whether enterprises will demand proof before autonomous software gets more authority, or after the first polished apology arrives with an incident report attached.

Synthefy

Synthefy just raised a $6.5M Seed round to build foundation models for the data that actually keeps companies alive: tables, transactions, sensor readings, inventory, pricing, risk, and every other row-and-column headache that never learned how to chat.

Wing Venture Capital led the round, with Haystack, Samsung Next, Canonical, and Lightscape participating. AI leaders Srinivas Narayanan, Aparna Chennapragada, and Manohar Paluri also invested, betting that the next model category will spend less time writing poems and more time making numbers useful.

Synthefy calls the category Structured Data Foundation Models. The pitch is straightforward: most businesses still rebuild the same machine-learning workflow for every dataset, then pay again in feature engineering, training, tuning, deployment, and maintenance when the problem changes.

Nori V1 is Synthefy’s answer. The open-weight model takes labeled context and new rows, then returns predictions without fitting a separate model or running a fresh hyperparameter search for every use case. The company has released the code and weights under Apache 2.0 while building managed API, private deployment, governance, integration, and support layers around it.

Synthefy says Nori has already passed 500,000 downloads, and its published benchmarks place the 30M-parameter model in the same competitive conversation as systems many times its size. Those are company-reported results, not an independent referee’s verdict, but the early developer interest is hard to dismiss.

Demand forecasting, fraud detection, dynamic pricing, predictive maintenance, healthcare risk, and infrastructure planning all live on structured data. A reusable model layer that shortens initial evaluation from weeks or months to minutes could change the economics of testing these systems before a full production build.

CEO Somi Agarwal is building Synthefy with co-founders Sandeep Chinchali and Raimi Shah. Their backgrounds span Uber, UT Austin, Stanford, Caltech, Zscaler, and UIUC, a team profile that makes sense for a company trying to teach models the difference between a spreadsheet and a business decision.

The new capital will expand research and engineering, fund the next generation of Nori, and support industry partnerships. The interesting question now is whether structured-data foundation models become a durable enterprise layer, or whether classical machine learning keeps charging companies rent for rebuilding the same house on every dataset.

Ampaire

Ampaire just closed a $19M Series B, and the real story is not another aviation startup promising a miracle aircraft from a rendering. It is a company betting that the fastest route to cleaner flight runs through known aircraft and existing airports.

DiamondStream Partners led the round, with strategic participation from Alaska Star Ventures and IAGi Ventures. Airline-backed capital brings operating reality into the room before a product meets a route schedule and maintenance program.

Ampaire has chosen the retrofit path. Its AMP-H570 integrated parallel hybrid-electric system combines combustion and electric propulsion, while the Eco Caravan converts the Cessna Grand Caravan. The argument is practical: reduce fuel use and emissions without asking regional operators to abandon familiar aircraft or wait for a new charging network.

The company says its hybrid-electric fleet has flown more than 38,000 test miles and that the Eco Caravan demonstrated roughly 54% to 57% lower total fuel burn than the legacy turboprop configuration. Those are company-reported flight-test figures. Certification and repeatable economics still decide whether engineering becomes infrastructure.

This capital is meant to expand route operations under the FAA eIPP program, produce more Eco Caravan aircraft, grow engineering and operations, strengthen suppliers, build manufacturing capability, and advance certification. The FAA approved the AMP-H570's G-1 certification basis in 2025, but that is not certification of the product. Aviation makes every ambitious sentence report to paperwork, testing, safety evidence, and time.

Ampaire says the Series B brings total funding to $68M, including about $25M in non-dilutive grants and contracts. That total is not simply venture equity. Government-backed technical work and private capital are carrying different pieces of commercialization.

Co-founder and CEO Kevin Noertker, co-founder and Executive Tech Fellow Cory Combs, and CTO Ed Lovelace have spent years moving Ampaire from prototype flights toward a certifiable, manufacturable system. Now supplier readiness, aftermarket support, and airline economics have to keep pace.

The broader signal is bigger than one round. Cleaner aviation may scale first through disciplined upgrades to existing fleets, not wholesale replacement of everything parked at the gate. Sometimes the bold move is not starting over. It is making the installed base meaningfully better. The next milestone is commercial entry into service with the evidence to earn operator trust.